source
- FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimabThe U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
- AI drugmaker Isomorphic Labs raises $5 billion in Series C roundIsomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…